Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAVEN 2: Emicizumab in Pediatric Hemophilia A
NCT02795767Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2016
- Primary completion
- Apr 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, open-label trial of emicizumab in hemophilia A (3 cohorts), sponsored by Roche. Primary endpoints: Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds at 52 weeks, Model-Based Annualized Bleed Rate (ABR) for All Bleeds at 52 weeks and 3 more. Started Jul 2016; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02795767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795767.